Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01619683 · ClinicalTrials.gov registry record · Phase 3
Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism
A Phase 3 study, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT01619683 is a Phase 3 study that has completed, run by Repros Therapeutics. The registered enrollment target is 300 participants.
The verdict
NCT01619683, a Phase 3 study, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
To determine the effects of 12 months of treatment with Androxal on bone mineral density in men with secondary hypogonadism.
Interventions
- DRUG Placebo
- DRUG enclomiphene citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2012-09 |
| Est. Completion | 2014-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01619683
The ClinicalTrials.gov registry entry for NCT01619683 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01619683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01619683 about?
NCT01619683 is a clinical study titled "Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism". To determine the effects of 12 months of treatment with Androxal on bone mineral density in men with secondary hypogonadism.
What is the current status of trial NCT01619683?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2012-09. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01619683?
The interventions under investigation include: Placebo (DRUG), enclomiphene citrate (DRUG).
Who is sponsoring clinical trial NCT01619683?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.